You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

The Nurse View: Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

  • Authors: Karen Drucker, MS, ANP; Theresa W. Gillespie, PhD, RN; Jacquelyn Lauria, MS, RN, APN-C
  • CE Released: 12/28/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/28/2018
Start Activity


Target Audience and Goal Statement

This activity is intended for nurses and nurse practitioners.

The goal of this activity is to provide education on the use of CDK4/6 inhibitors in the management of HR-positive metastatic breast cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Likely treatment paths for patients with HR-positive MBC
  • Have greater competence related to
    • Identification of common CDK4/6 inhibitor-related side effects
    • Prevention and management of CDK4/6 inhibitor-related side effects


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest.  The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Karen Drucker, MS, ANP

    Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer, New York, New York

    Disclosures

    Disclosure: Karen Drucker, MS, ANP, has disclosed no relevant financial relationships.

    Ms Drucker does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Drucker does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty

  • Theresa W Gillespie, PhD, RN

    Professor, Department of Surgery and Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia

    Disclosures

    The opinions expressed are those of Ms Gillespie and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Gillespie’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.
    Disclosure: Theresa W. Gillespie, PhD, RN, has disclosed no relevant financial relationships.

    Dr Gillespie does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Gillespie does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Jacquelyn H. Lauria, MS, RN, APN/CS

    Stacy Goldstein Breast Cancer Center, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

    Disclosures

    Disclosure: Jacquelyn Lauria, MS, RN, APN-C, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Puma Biotechnology

    Ms Lauria does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Lauria does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Sarah Williams, PhD

    Lead Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Sarah Williams, PhD, has disclosed no relevant financial relationships.

CE Reviewer/Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

The Nurse View: Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

Authors: Karen Drucker, MS, ANP; Theresa W. Gillespie, PhD, RN; Jacquelyn Lauria, MS, RN, APN-CFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CE Released: 12/28/2017

Valid for credit through: 12/28/2018

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Medscape Education makes these downloadable slides available solely for non-commercial use by you as a reference tool. You may not use these slides for any commercial purpose or provide these slides to any third party for such party’s use for any commercial purpose. Please refer to the Medscape Terms of Use for additional details.

  • Print